$MRNA one of the most Corona virus associated stock has experienced sharp increase in prices – the stock hit Circuit breakers not One but Eight Times.
We own $NTGN which $BNTX is buying!
$BNTX looks very interesting for this reason: the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders. does it have any corona virus application?
our most successful holding $TNXP up more than 200% in just 2 days!
Moderna Inc NASDAQ: MRNA
Go
Health Care : Biotechnology | Mid Cap Growth
Company profile
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
BioNTech SE NASDAQ: BNTX
Go
Health Care : Biotechnology | | Based in Germany
Company profile
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Neon Therapeutics Inc NASDAQ: NTGN
Go
Health Care : Biotechnology | Small Cap Growth
Company profile
Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.
Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP*
Go
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Small Cap Value
Company profile
Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
Important Disclosure: We’ve open position in TONIX, $TNXP and Neon $NTGN
Editor Daily Stock Deals
Source: WHO, The Guardian, CNBC, OxBridge Research, Daily Stock Deals
Get in your inbox FREE insightful analysis that affects your bottom line
learn more.........
Find out the origins of Corona Virus and where it started
